Cullinan Oncology, Inc. announced that Jeffrey (Jeff) Jones, M.D., MPH, MBA will join the company as Chief Medical Officer and Anne-Marie (Annie) Martin, Ph.D., has been appointed to the Company's Board of Directors. Dr. Jones joins Cullinan Oncology from Bristol Myers Squibb where he held positions of increasing responsibility in oncology clinical development, most recently as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases. Dr. Martin brings to Cullinan Oncology over 25 years of translational medicine and clinical research expertise, and is currently Senior Vice President, Global Head of the Experimental Medicine Unit at GlaxoSmithKline.

Most recently, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases, where he led the development and lifecycle management strategy for Reblozyl®, across both benign and malignant hematology indications. In prior roles, Dr. Jones led disease area, clinical and business development strategy for B-cell malignancies across a diverse portfolio of small and large molecules from early-to-late-stage development. Dr. Jones received his M.D. from University of Michigan Medical School in Ann Arbor, Michigan and completed his residency in internal medicine at McGill University Faculty of Medicine in Montreal and a fellowship in hematology and medical oncology at MD Anderson Cancer Center in Houston, Texas.

Dr. Jones also holds an M.B.A. from The Ohio State University Fisher College of Business and an M.P.H. from the University of Texas School of Public Health.